



**CANNABINOID**  
conference 2017

IACM 9<sup>th</sup> Conference on Cannabinoids in Medicine  
Maritim Hotel Cologne, Germany, 29-30 September 2017

<http://cannabinoidconference2017.org>

## Program

Last update: 27 February 2017

## Friday, September 29

| 08:00 - 17:00 |                           | Registration  |
|---------------|---------------------------|---|
|               |                           | Presentation  |
| 09:00 - 09:40 | <b>Where do we stand?</b> | <b>Session I: Accepted medical uses and medications</b><br><br><u>Donald Abrams</u> : "Cannabis-based medicines: an introductory overview of all the major clinically relevant known knowns and known unknowns" |
| 09:40 – 10:20 |                           | <u>NN</u> : "Current cannabis-based medicines: a pharmacologist's perspective"  |
| 10:20 – 11:00 |                           | <u>Kirsten Müller-Vahl</u> : "Current cannabis-based medicines: a clinician's perspective"  |
| 11:00 – 11:15 |                           | Break   |
| 11:15 – 11:30 |                           | Submitted talk  |
| 11:30 – 11:45 |                           | Submitted talk  |
| 11:45 – 12:00 |                           | Submitted talk  |
| 12:00 – 12:15 |                           | Submitted talk  |
| 12:15 – 12:30 |                           | Submitted talk  |

|               |  |   |
|---------------|--|---|
| 12:30 – 13:00 |  | Questions from a panel of experts: “What information do patients and their clinicians need?”  |
| 13:00 – 15:00 |  | Lunch and <b>poster session 1</b>   |
| 15:00 – 15:40 |  | <b>Session II: Genetics, strains and quality</b><br><u>Ethan Russo</u> : “Chemovars (and a comparison of sativa & indica)”                                    |
| 15:40 – 16:20 |  | <u>Jahan Marcu</u> : “Nature, variability & safety of marketed cannabis (NB pesticides) & how to optimize the safety & medical efficacy of marketed cannabis” |
| 16:20 - 16:35 |  | Break   |
| 16:35 – 17:05 |  | <b>Session III: Laws and politics</b><br><u>Mark Ware</u> : “Impact of new regulations on medical and recreational cannabis”                                  |
| 17:05 – 17:20 |  | <u>Jeffrey Hergenrather</u> : “Country report: USA”   |
| 17:20 – 17:35 |  | <u>Ilija Reznik</u> : “Country report: Israel”  |
| 17:35 – 17:50 |  | <u>Franjo Grotenhermen</u> : “Country report: Germany”  |
| 17:50 – 18:05 |  | <u>Sébastien Béguerie</u> : “Country report: France”  |
| 18:05 – 18:35 |  | Questions from a panel of experts: “What are the best (and worst) ways forward for patients and their clinicians?”  |
| 19:00 – 22:00 |  | <b>Dinner of IACM partner organizations and ambassadors</b>   |

## Saturday, September 30

|                      |                        |   |
|----------------------|------------------------|---|
| <b>08:15 - 12:00</b> |                        | <b>Registration</b>   |
|                      |                        | Presentation  |
| 09:00 – 09:40        | <b>Where do we go?</b> | <b>Session IV: Emerging new indications</b><br><u>Jonathan Page</u> : “Future exploitation of phytocannabinoids in the clinic - most promising future directions” |

|               |  |  |
|---------------|--|--|
| 09:40 – 10:20 |  | <u>Roger Pertwee</u> : “Future exploitation in the clinic of the endocannabinoid system and of synthetic drugs - most promising future directions” |
| 10:20 – 11:00 |  | <u>Daniela Parolaro</u> : “Phytocannabinoids in mental disorders”  |
| 11:00 – 11:15 |  | Break  |
| 11:15 – 11:55 |  | <u>Guillermo Velasco</u> : “Promising future directions: cannabinoid medicines versus cancer”  |
| 11:55 – 12:10 |  | Submitted talk   |
| 12:10 – 12:25 |  | Submitted talk   |
| 12:25 – 12:40 |  | Submitted talk   |
| 12:40 – 12:55 |  | Submitted talk   |
| 12:55 – 15:00 |  | Lunch and <b>poster session 2</b>  |
|               |  | <b>Session V: Knowledge and education</b>  |
| 15:00 – 15:40 |  | <u>Franjo Grotenhermen</u> : “Promising indications with limited clinical evidence”  |
| 15:40 – 16:20 |  | <u>Raquel Peyraube</u> : “What questions do clinicians and patients have on a treatment with cannabis-based medicines?”                            |
| 16:20 – 17:00 |  | Questions from a panel of experts: “What should clinicians, patients and regulators know? What questions are still waiting for an answer?”         |
| 17:00 – 17:15 |  | Break  |
| 17:15 – 18:30 |  | <b>IACM General Meeting</b>  |
| 19:00 – 22:00 |  | <b>Dinner with Award Ceremony</b>  |

### Special thanks

Special thanks by the IACM Board of Directors go to our platin sponsor Bedrocan ([www.bedrocan.com](http://www.bedrocan.com)) for their extraordinary contribution to the conference to allow us to invite the best speakers for every topic and make this program possible.